Dual blockade of TNF and IL-17A using the combination of soluble IL-17 receptor (sIL-17R) and TNF binding protein (TNFBP) [30] or combined single/dual variable domain bispecific neutralizing antibodies [31] was shown to be effective in the human TNF transgenic mouse model of arthritis and the collagen-induced arthritis model (i.e., preclinical models of rheumatoid arthritis (RA)). Here, TNF is linked to arthritic joint disease.